Fluorescent lymphography for sentinel lymph nodes biopsy
Abstract
The utility of ICG fluorescent lymphography is very common among SLN detection. This method is used to evaluate different diseases including skin melanoma, stomach cancer, cervical carcinoma and penile cancer. Our research is focused on using ICG lympphography for breast cancer treatment. Aim of research. Evaluation of the possibility of ICG lymphography method usage for SLN detection while breast cancer treatment. Methods and data. 200 I-II-A-B breast cancer deceased previously supervised and conducted combined and/or complex therapy including reconstructive plastic surgery were made operations. The first group of patients was performed an SLN biopsy, a modified radical mastectomy ± reconstruction or organ-sparing surgery and axillary lymphadenectomy leveled I-II. The second group of patients was performed an SNLB, mastectomy ± reconstruction or organ-sparing operation. Results of the research. Major diagnostic characteristics of the method: frequency of SLN finding is 98-100%. False negative result: 3.4-9%. While monitoring the patients for 36 months there was received no evidence of local-regional metastasis. Conclusion. According to the diagnostic characteristics of fluorescent lymphography is not inferior to the international standard with radioisotope tracer. The importance of the method of fluorescent lymphography for the clinical practice of an oncosurgeons is extremely high.
About the Authors
A. S. Soloveva
Pirogov Russian National Research Medical University (RNRMU); FSBI «N.N. Blokhin national medical research center of oncology» of the Ministry of Health of Russia
Russian Federation
Russian Federation
V. A. Sobolevskiy
FSBI «N.N. Blokhin national medical research center of oncology» of the Ministry of Health of Russia
Russian Federation
Russian Federation
V. A. Khaylenko
FSBI «N.N. Blokhin national medical research center of oncology» of the Ministry of Health of Russia; Pirogov Russian National Research Medical University (RNRMU)
Russian Federation
Russian Federation
O. V. Krohina
FSBI «N.N. Blokhin national medical research center of oncology» of the Ministry of Health of Russia
Russian Federation
Russian Federation
O. A. Anurova
«Frau Klinik»
Russian Federation
Russian Federation
N. M. Shakirova
FSBI «N.N. Blokhin national medical research center of oncology» of the Ministry of Health of Russia
Russian Federation
Russian Federation
D. V. Khaylenko
FSBI «N.N. Blokhin national medical research center of oncology» of the Ministry of Health of Russia
Russian Federation
Russian Federation
R. B. Azimova
FSBI «N.N. Blokhin national medical research center of oncology» of the Ministry of Health of Russia
Russian Federation
Russian Federation
V. Y. Ivashkov
FSBI «N.N. Blokhin national medical research center of oncology» of the Ministry of Health of Russia
Russian Federation
Russian Federation
O. Y. Gorbacheva
FSBI «N.N. Blokhin national medical research center of oncology» of the Ministry of Health of Russia
Russian Federation
Russian Federation
R. M. Dokolin
FSBI «N.N. Blokhin national medical research center of oncology» of the Ministry of Health of Russia
Russian Federation
Russian Federation
S. V. Sopromadze
FSBI «N.N. Blokhin national medical research center of oncology» of the Ministry of Health of Russia
Russian Federation
Russian Federation
V. I. Tyan
FSBI «N.N. Blokhin national medical research center of oncology» of the Ministry of Health of Russia
Russian Federation
Russian Federation
N. S. Brekhunec
Pirogov Russian National Research Medical University (RNRMU)
Russian Federation
Russian Federation
T. V. Piven
FSBI «N.N. Blokhin national medical research center of oncology» of the Ministry of Health of Russia
Russian Federation
Russian Federation
N. I. Mekhtieva
FSBI «N.N. Blokhin national medical research center of oncology» of the Ministry of Health of Russia
Russian Federation
Russian Federation
References
1. Злокачественные новообразования в России в 2016 году (Заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М., 2018.
2. Tvedskov TF, Jensen MB, Ejlertsen B, Christiansen P, Balslev E, Kroman N. Prognostic significance of axillary dissection in breast cancer patients with micro metastases or isolated tumor cells in sentinel nodes: a nationwide study. Breast Cancer Res Treat. 2015;153(3):599-606.
3. Sackey H, Magnuson A, Sandelin K, Liljegren G, Bergkvist L, Fulep Z et al. Arm lymphoedema after axillary surgery in women with invasive breast cancer. Br J Surg. 2014;101(4): 390-397.
4. Giuliano AE, McCall L, Beitsch P, Whitworth PW, Blumencranz P, Leitch AM et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases. Ann Surg. 2016;264(3):413-420.
5. Coates AS, Winer EP, Goldhirsch A et al. Tailoring therapies - improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Annals of Oncology. 2015;26:1533-1546.
6. Giammarile F, Alazraki N, Aarsvold JN et al. The EANM and SNMMI practice guideline for lymphoscintigraphy and sentinel node localization in breast cancer. Eur J Nucl Med Mol Imaging. 2013;40:1932-1947.
7. Kitai T, Inomoto T, Miwa M, Shikayama T. Fluorescence navigation with indocyanine green for detecting sentinel lymph nodes in breast cancer. Breast Cancer. 2005;12:211-215.
8. Ballardini B, Santoro L, Sangalli C et al. The indocyanine green method is equivalent to the "mTc-labeled radiotracer method for identifying the sentinel node in breast cancer: a concordance and validation study. Eur J Surg Oncol. 2013;39(12):1332-1336.
9. Vera DR, Wallace AM, Hoh CK. A synthetic macromolecule for sentinel node detection: (99m)Tc-DTPA-mannosyl-dex-tran. J Nucl Med. 2001;42:951-959.
10. Motomura K, Inaji H, Komoike Y et al. Sentinel node biopsy guided by indocyanine green dye in breast cancer patients. Jpn J Clin Oncol. 1999;29:604-607.
11. Rossi EC, Ivanova A, Boggess JF. Robotically assisted fluores-cenceguided lymph node mapping with ICG for gynecologic malignancies: a feasibility study. Gynecol Oncol. 2012;124:78-82.
12. Портной СМ, Кузнецов АВ, Шакирова НМ, Козлов НА, Масляев АВ, Карпов АВ и соавт. Биопсия сигнального лимфатического узла с использованием флуоресцентной лимфографии у больных раком молочной железы. Методические особенности. Онкогинекология. 2017; (21):11-18.
Review
For citations:
Soloveva A.S., Sobolevskiy V.A., Khaylenko V.A., Krohina O.V., Anurova O.A., Shakirova N.M., Khaylenko D.V., Azimova R.B., Ivashkov V.Y., Gorbacheva O.Y., Dokolin R.M., Sopromadze S.V., Tyan V.I., Brekhunec N.S., Piven T.V., Mekhtieva N.I. Fluorescent lymphography for sentinel lymph nodes biopsy. Bone and soft tissue sarcomas, tumors of the skin. 2019;11(2):49-54. (In Russ.)
Views:
247
Email this article 
